The congressionally funded Phase II Clinical Trials Consortium has just launched a terrific new public website. Three Consortium trials are now open: Lovastatin for learning disabilities; Rapamycin for plexiform tumors; and the newly added trial of Everolimus for optic pathway glioma. For more details on each trial, participating sites and entry criteria, as well as background information on the Consortium, please visit www.nfconsortium.org
The NF Consortium is dedicated to conducting clinical trials to improve the quality of life of persons with neurofibromatosis. The Consortium consists of nine clinical sites around the US and an Operations Center to coordinate Consortium activities at University of Alabama at Birmingham. It was formed in 2006 with funding secured through a Congressionally Directed Medical Research Program which has supported NF research since 1996, in part due to lobbying by individuals and organizations including the Children’s Tumor Foundation that represent the neurofibromatosis community.
